Manufacturer
Abio
Contents
Clopidogrel
Indication
Prevention of artherothrombotic events eg, recent MI, stroke, established peripheral arterial disease; acute coronary syndrome; patients suffering from MI (from a few days until <35 days), ischaemic strokes (from 7 days until <6 mth); non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) including patient undergoing stent replacement following percutaneous coronary intervention. In combination with ASA for ST segment elevation acute MI in medically treated patients and eligible for thrombolytic therapy.
Instruction
May be taken with or without food.
Drug interaction
CYP2C19 eg, proton-pump inhibitors reduce drug levels of the active metabolite and reduction of clinical efficacy. Warfarin and glycoprotein IIb/IIIa inhibitors, heparin and thrombolytics may increase the intensity of bleeding. May increase occult GI blood loss with other NSAIDs including COX-2 inhibitors.
Malaysia
